Skip to main content

Table 1 Trials characteristics

From: The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov

  Number Percent
Trial phase
Phase I/II 48 17.3
Phase II 200 72.2
Phase II/III 4 1.4
Phase III 25 9.0
Sponsor
NIH 33 11.9
Industry 60 21.7
Other 184 66.4
Enrollment size
0–50 136 49.1
51–100 65 23.5
101–200 40 14.4
201–300 6 2.2
301-more 16 5.8
NR 14 5.1
Number of centers
1 97 35.0
2 6 2.2
multicenter 174 62.8
Number of arms
1 196 70.8
2 67 24.2
≥3 14 5.1
Treatment allocation
Non-randomized 209 75.5
Randomized 68 24.5
Masking
Open-label 257 6.9
Single-blind 1 0.4
Double-blind 19 92.8
Region
United states 186 67.1
Europe 65 23.5
Asia 26 9.4
  1. Trial characteristics are based on the clinical trials which are advanced or metastatic sarcoma specific. Abbreviations: NIH National Institutes of Health, NR null value